proximod
/ Jiankuan (Suzhou) Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 14, 2026
PROXIMA: Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.
(clinicaltrials.gov)
- P2 | N=179 | Completed | Sponsor: Peking University People's Hospital
New P2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
October 03, 2026
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
(clinicaltrials.gov)
- P3 | N=590 | Not yet recruiting | Sponsor: Jiankuan (Suzhou) Biotechnology Company Limited
New P3 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
April 11, 2024
BJXH-2017-001: Proximod Pharmacokinetics In Healthy Subjects
(clinicaltrials.gov)
- P1 | N=134 | Completed | Sponsor: Longevity Inc.
New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
April 11, 2024
BJXH-2021-001: Proximod Pharmacokinetics in Healthy Subjects and Patients With Rheumatoid Arthritis
(clinicaltrials.gov)
- P1 | N=22 | Completed | Sponsor: Longevity Inc.
New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
1 to 4
Of
4
Go to page
1